March 31, 2021
Otsuka Pharmaceutical and partner Akebia Therapeutics said on March 30 that a new drug application has been submitted in the US for their hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat. Cambridge, Massachusetts-based Akebia filed the drug with the FDA for...read more